Program
GSK3882347
A development code.
In GlaxoSmithKline's pipeline, FimH antagonist
. Its studies are mostly in Urinary Tract Infections, led by GlaxoSmithKline.
Furthest: phase 1, since Jul 23, 20203 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 30 open or running | phase 1since Jul 23, 2020 | Jul 23, 2020 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
GSK3882347
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2020First study: phase 1 study in Urinary Tract InfectionsFirst studyNCT04488770 · 61 enrolled · United Kingdom
- Nov 15, 2021Phase 1 study in Urinary Tract InfectionsNCT05138822 · 140 enrolled · United States
- Feb 27, 2023Phase 1 study in Urinary Tract InfectionsNCT05760261 · 27 enrolled · United Kingdom
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“FimH antagonist”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05760261Urinary Tract Infections · United Kingdom | 1 | Completed | Aug 13, 2024 | 27 |
| NCT05138822Urinary Tract Infections · United States | 1 | Completed | Dec 3, 2024 | 140 |
| NCT04488770Urinary Tract Infections · United Kingdom | 1 | Completed | May 14, 2021 | 61 |
How it is read
Names in the registry
- “GSK3882347”, 3 entries
Codes read as this program: GSK3882347.
Conditions, from the studies’ own filings
- Urinary Tract Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.